Company intelligence / Profile preview
Institute for Diabetes Discovery
United States
- Ownership
- Private
- Development stage
- Other
01
Overview
The company’s main asset was lidorestat (IDD-676), an AKR1B1 inhibitor for diabetic nephropathy, which reached phase 2 clinical trials but was later discontinued. There are no active clinical results or current ongoing programs from the company
- Therapeutic areas
- NephrologyEndocrinology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Merck Serono SA (development partnership for lidorestat)
Beyond the preview
Go deeper on Institute for Diabetes Discovery.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Institute for Diabetes Discovery.